Pharmacologic Stress Agents

Agent

Which agent: exercise if possible (AHA 2026). Possible dynamic narrowing (AAOCA with an inter-arterial or intramural course, myocardial bridge): dobutamine, not a vasodilator (AHA 2026; Fares 2019; ASNC 2026 p45, adult). Fixed obstruction, fistula: a vasodilator is an option.

Adenosine

Contraindications first: shared section

Dose
Pediatric140 mcg/kg/min (0.14 mg/kg/min), 3 min before contrast. Adequacy and safety not thoroughly established in children. SCMR CHD 2013
Fares 2019
ProposedUp to 210 mcg/kg/min. No pediatric cohort read escalated. Fares 2019
Give, watch, stop
PediatricTwo IV lines. Continuous ECG, BP every 2 min. SCMR CHD 2013
PediatricStop for persistent or symptomatic heart block, significant hypotension or severe respiratory difficulty.SCMR CHD 2013
Reverse
PediatricStop the infusion: half-life <10 s, Adult. No pediatric reversal dose in any document read.ASNC 2026
Fares 2019
SCMR CHD 2013
AdultNot for a seizure (caffeine: sources disagree). Rescue, rarely needed: aminophylline 50–125 mg over 30 s, to 250 mg at most. When to reverse, Adult. ASNC 2026
FDA label
Abidov 2018
Adult and not child-specific rows
Dose
Not child-specific140, up to 210 mcg/kg/min.SCMR 2025
Adult140, 170, then 210 mcg/kg/min, 7 min at most. Karamitsos 2010
SCMR 2020
Adult140 mcg/kg/min for 6 min, or 4 min as an alternative. Higher risk (borderline hypotension, controlled asthma): start at 70–110 mcg/kg/min for 1 min, then 140. No dose above 140 printed.ASNC 2026

Regadenoson

Contraindications first: shared section

Dose, single IV bolus
Pediatric6–8 mcg/kg, up to 400 mcg: most common.SCMR 2025
Pediatric8 mcg/kg if <40 kg; 400 mcg if ≥40 kg. Wilkinson 2019
Noel 2018
Proposed10 mcg/kg if <40 kg; 0.4 mg (400 mcg) if >40 kg. Top of the range: 1 patient of 38 in Patel 2022. Fares 2019
Pediatric6–10 mcg/kg, maximum 400 mcg. Patel 2022
AdultFixed adult dose: not under 40 kg (our note). ASNC 2026 Table 10 prints 0.4 mg down to 25 kg and 50 lb: 16 to 18 mcg/kg, about twice the 8 mcg/kg above (our arithmetic). ASNC 2026
FDA label
Give, watch
PediatricOne IV line. BP every 3 min; monitor 1 hour after the study. Wilkinson 2019
PediatricHypotension: 8 of 46 needed phenylephrine; sedation an independent risk. Wilkinson 2019
AdultAsystole and heart block within minutes, rarely; resuscitation equipment and trained staff at hand. FDA label
ASNC 2026 p21
AdultSeizure reported; ask about seizure history. With a history: aminophylline with caution, routine doses too (ASNC 2026 p51, FDA labels).FDA label
ASNC 2026
Aminophylline label
Reverse: aminophylline IV, slowly
AdultNot for a seizure. Aminophylline, theophylline not recommended: may lower the seizure threshold. No pediatric document read addresses it. First line in adults is IV lorazepam (no pediatric dose). Its label: status epilepticus not established in pediatric patients; not for neonates; ventilatory support at hand. Abidov 2018
FDA label
ASNC 2026
AdultCaffeine in a seizure, sources disagree: FDA labels and Abidov 2018 advise against every methylxanthine, caffeine included; ASNC 2026 prefers IV caffeine for reversal. FDA labels
Abidov 2018
ASNC 2026
AdultReverse for severe or symptomatic hypotension, sustained arrhythmia, symptomatic AV block, wheezing, poor perfusion, moderate to severe angina, or intolerable side effects. Full list.ASNC 2026 Table 5, p32
PediatricNo weight-based rescue dose has been tested in any document read.
PediatricRoutine reversal, sources disagree: the pediatric series below gave it routinely; ASNC 2026 (nuclear) and Abidov 2018, adult, advise against.Wilkinson 2019
Patel 2022
ASNC 2026
Abidov 2018
Pediatric0.25 mg/kg under 40 kg, routine after stress imaging. Not tested as a rescue dose. Wilkinson 2019
Noel 2018
Pediatric50 mg over 40 kg, routine: a 5-fold step from 0.25 mg/kg.Noel 2017
Noel 2018
Pediatric75 mg fixed, routine; median 61 kg. No minimum weight printed: 15 mg/kg at 5 kg.Patel 2022
Proposed50 mg fixed, no weight range given, rescue if side effects develop. At 5 kg this is 10 mg/kg, 40 times the 0.25 mg/kg above; 53 times at 3.8 kg, Wilkinson 2019’s smallest. Our arithmetic. Fares 2019
AdultNot for a seizure. Rescue aminophylline 50–125 mg over 30 s, may repeat, to 250 mg at most (ASNC 2026); 50–250 mg (FDA label). Pediatric rescue untested: weight warnings above. Arrhythmogenic: caution (SCMR 2020). ASNC 2026
FDA label
SCMR 2020
Abidov 2018
Adult rows: dose, study arms
Dose
Adult0.4 mg, about 10 s; 20–30 s may lessen hypotension. SCMR 2020
ASNC 2026
FDA label
Reverse: aminophylline IV, slowly
Adult100 mg routine at many sites, with caution: arrhythmogenic. 125 mg, study arm: reversal only partial at 15 min. SCMR 2020
Bhave 2012

Dipyridamole

Contraindications first: shared section

Dose
PediatricNo pediatric dose in any document read. Fares 2019
Adult0.142 mg/kg/min (0.57 mg/kg total) over 4 min; 0.56 mg/kg in ASNC 2026. 60 mg at most. FDA label
ASNC 2026
Vasu 2013
Give, watch, reverse
ReviewTwo IV lines. Half-life 30–45 min. Fares 2019
AdultNot for a seizure (caffeine: sources disagree). Rescue, frequently needed: aminophylline 50–125 mg over 30 s, to 250 mg at most (ASNC 2026); 50–250 mg (FDA label). No pediatric dose. When to reverse, Adult. ASNC 2026
FDA label
Abidov 2018

Dobutamine, with or without atropine

Contraindications first: shared section

Dose, two IV lines
ProposedStart 5–10 mcg/kg/min, up every 3 min, maximum 40. Fares 2019
Pediatric10, 20, 30, 40 mcg/kg/min; stages 3 or 3–5 min. AHA 2026
Strigl 2009
Atropine contraindications
Pediatric0.01 mg/kg, Table 2: no increment or primary source. Label: usual initial 0.01–0.03 mg/kg, not well studied; coronary limit 0.03–0.04 mg/kg total. AHA 2026
FDA label
Target heart rate
Proposed85% of maximal heart rate for age.Fares 2019
PediatricSeries ran to 85% × (220 − age). Not established in children: reached in 6 of 32, and 10 of 13 awake and older. Strigl 2009
Stagnaro 2023
AHA 2026
Watch, stop
PediatricContinuous ECG, oximetry; BP every 2 min. ST segments unreadable in the magnet. Strigl 2009
PediatricStop criteria: none printed for children beyond the heart rate target. Adult: new wall motion abnormality, serious side effect or target heart rate (SCMR 2020); ASNC 2026 list. Strigl 2009
SCMR 2020
PediatricA negative study does not exclude anatomic obstruction. AHA 2026
Beattie 2025
Reverse
PediatricStop the infusion: half-life 2 min. Esmolol or IV metoprolol at hand: no pediatric dose in any document read. Strigl 2009
Stagnaro 2023
Adult rows; low dose
Dose
Not child-specificViability, contractile reserve: 5, 10, 20 mcg/kg/min. AHA 2026
AdultFrom 10, up 10 mcg/kg/min every 3 min, typically to 40.SCMR 2020
AdultFrom 5 or 10, every 3 min, to 40; 50 mcg/kg/min for 3 more min in selected patients.ASNC 2026
Atropine
Adult0.25 mg fractions or 0.5 mg increments, both printed; maximum 2 mg. ASNC 2026: divided 0.25–0.5 mg, same maximum, after 40 mcg/kg/min or in some cases after 30.SCMR 2020
ASNC 2026
Target heart rate
Adult85% × (220 − age).SCMR 2020
ASNC 2026

Contraindications; when to stop

Sources: FDA labels for regadenoson, adenosine, dipyridamole, dobutamine, atropine, aminophylline, lorazepam; ASNC 2026; AHA 2026; SCMR 2020; SCMR CHD 2013; Fares 2019; Robbers-Visser 2009. Labels not read, doses not shown: theophylline, caffeine, esmolol, metoprolol, nitroglycerin, phenylephrine.

No list is complete; an empty list does not clear a patient.

All agents
AdultCaution: severe pulmonary hypertension; significant left main stenosis or high-risk coronary anatomy.ASNC 2026 Table 4
AdultHeart transplant, sources disagree: exercise, regadenoson or dobutamine preferred; adenosine, more bradyarrhythmia and AV block.ASNC 2026 p47
PediatricHeart transplant: AHA 2026 Table 1, uncited: pediatric literature shows adenosine stress CMR safe despite conduction concerns. Regadenoson CMR (Husain 2021): no major events in 24, mean 16 y. AHA 2026 Table 1
Husain 2021
Adenosine, regadenoson, dipyridamole
PediatricAdenosine: second or third degree heart block; sinus node dysfunction; severe asthma or obstructive pulmonary disease; pregnancy.SCMR CHD 2013
ReviewAll three: SSS; high degree AV block; recent ACS; hypotension. Bronchospasm or asthma: relative (adenosine, dipyridamole), rare (regadenoson). Fares 2019
AdultTaking dipyridamole: no regadenoson or adenosine within 48 h. IV dipyridamole instead (no pediatric dose), oral continued; dobutamine second line. ASNC 2026 Table 3
Robbers-Visser 2009
AdultAsthma, sources disagree: active disease with regular inhalers excludes all three (SCMR 2020); adenosine label, known or suspected; ASNC 2026, ongoing wheezing or a recent exacerbation, regadenoson preferred if stable.SCMR 2020
FDA label
ASNC 2026
AdultSeizure: adenosine, regadenoson: ask about seizure history; contraindicated with active seizures within 6 months (ASNC 2026 Table 3), a caution with dipyridamole; avoid if antiseizure medication is being titrated (pp 50-51).FDA labels
ASNC 2026
AdultSinus node disease, sources disagree: regadenoson and adenosine labels contraindicate it without a functioning pacemaker; ASNC 2026 p44, generally acceptable; p28, a reason for dobutamine.Regadenoson label
Adenosine label
ASNC 2026
Dobutamine, atropine
AdultFDA label: idiopathic hypertrophic subaortic stenosis; hypersensitivity.FDA label
ReviewRecent ACS; electrical or hemodynamic instability.Fares 2019
ReviewCHD: obstructed systemic ventricular filling or ejection; 2nd or 3rd degree AV block; history of sustained ventricular tachycardia.Robbers-Visser 2009
AdultAtropine, sources disagree: not with narrow-angle glaucoma, myasthenia gravis, obstructive uropathy or obstructive gastrointestinal disorders (SCMR 2020, ASNC 2026); its FDA label lists none, but warns of glaucoma, pyloric obstruction, urinary retention.SCMR 2020
ASNC 2026 pp 30-31
FDA label
Adult lists: ASNC 2026, SCMR 2020, FDA labels

Our note: numeric cut-offs here are adult; no document read gives pediatric ones. Mean resting systolic BP in Wilkinson 2019’s children was 90.4 mmHg, so neither ≤85 nor <90 mmHg reads across. The two adult documents differ on blood pressure: both are printed.

ASNC 2026, nuclear imaging
AdultAll agents, contraindicated: systolic BP at rest ≥200 or diastolic ≥110 mmHg; symptomatic hypotension, or systolic BP at rest ≤85 mmHg without symptoms; third-degree AV block without a functioning pacemaker; acute coronary syndrome within 2 days or with ongoing symptoms; acutely rising troponin; acute decompensated heart failure; uncontrolled or unstable arrhythmia; symptomatic severe aortic stenosis; acute pulmonary embolism; acute aortic syndrome; acute significant illness; cannot cooperate or stay still.ASNC 2026 Table 3
AdultAll agents, caution: severe pulmonary hypertension; significant left main stenosis or high-risk coronary anatomy; large unrepaired aortic aneurysm; asymptomatic severe aortic stenosis; significant electrolyte abnormalities; active endocarditis; recent stroke, TIA or severe carotid stenosis; significant anemia or blood loss. Avoid with hemoglobin <7 g/dL, or potassium <3 or >5.5 mmol/L (expert consensus).ASNC 2026 Table 4, pp 42, 46
AdultAdenosine, regadenoson, dipyridamole, contraindicated: second-degree Mobitz type 2 AV block or severe symptomatic bradycardia without a functioning pacemaker; symptomatic aortic aneurysm; caffeine within 12 h. Caution: heart rate ≤40 per min; junctional rhythm; acute left ventricular thrombus; caffeine within 24 h.ASNC 2026 Tables 3, 4
AdultRegadenoson, adenosine, seizure risk: large hemorrhagic CVA within 3 months, avoid; remote or questionable seizure history, many clinicians would proceed.ASNC 2026 pp 50-51
AdultDobutamine, contraindicated: acute left ventricular thrombus; hypertrophic obstructive cardiomyopathy or other significant LVOT obstruction; prior VT; symptomatic or severely enlarged aortic aneurysm; poorly rate-controlled atrial fibrillation or flutter. Caution: frequent PVCs or NSVT; beta blockers above low doses.ASNC 2026 Tables 3, 4
SCMR 2020, FDA labels
AdultAdenosine, regadenoson, dipyridamole: 2nd degree (type 2) or complete AV block; systolic BP <90 mmHg; hypertension >220/120 mmHg; sinus bradycardia <40 bpm; active bronchospastic disease, regular inhalers; hypersensitivity.SCMR 2020
AdultAdenosine, regadenoson: second- or third-degree AV block or sinus node dysfunction, unless a pacemaker functions. Adenosine: known or suspected bronchospastic lung disease. Regadenoson: obtain a seizure history. FDA labels
AdultDobutamine: hypertension ≥220/120 mmHg; unstable angina; severe aortic stenosis (gradient >60 mmHg or area <1 cm²); complex arrhythmias; hypertrophic obstructive cardiomyopathy; myocarditis, endocarditis or pericarditis; uncontrolled heart failure.SCMR 2020
AdultAminophylline: not with hypersensitivity to theophylline or ethylenediamine. Extreme caution: seizure disorders, cardiac arrhythmias other than bradyarrhythmias, active peptic ulcer.FDA label
AdultLorazepam: known sensitivity to benzodiazepines or its vehicle; acute narrow-angle glaucoma; sleep apnea syndrome; severe respiratory insufficiency unless mechanically ventilated; intra-arterial use; premature infants (benzyl alcohol). Ventilatory support must be readily available.FDA label
When to stop or reverse, Adult

Stop or reverse, any agent:

  • Moderate to severe angina.
  • ST depression >2 mm (horizontal or downsloping) with suspected ischemia; ST elevation >1.0 mm in leads without diagnostic Q waves, except V1 and aVR.
  • Sustained SVT or VT.
  • Symptomatic second- or third-degree AV block without a functioning pacemaker.
  • New LBBB or intraventricular conduction delay that cannot be told from VT.
  • Signs of poor perfusion (cyanosis, pallor).
  • Systolic BP <80 mmHg; systolic >230 and/or diastolic >115 mmHg.
  • The ECG or BP cannot be monitored; the patient asks to stop.
  • Symptomatic hypotension (systolic BP <90 mmHg).
  • Adenosine, regadenoson, dipyridamole: wheezing; bronchodilators and oxygen at hand (SCMR 2020; ASNC 2026 pp 22, 25, 28, 50).
  • Dobutamine with an ICD: heart rate within 20 bpm of the lowest programmed therapy rate.

Consider, any agent: persistent asymptomatic second-degree or complete AV block; other significant arrhythmia; ST depression >2 mm without suspected ischemia; severe or increasing chest pain of unclear cause. Vasodilators: less severe side effects or ischemic ECG changes. Dobutamine: systolic BP falling on consecutive readings, especially with ischemic ECG changes or angina: look for the cause, consider holding the rate or stopping.

ASNC 2026 Tables 5 and 6. ASNC 2026 revises the 2016 guideline (p2), which was not read. Abidov 2018’s list, based on it, differs: severe hypotension ≤80 mmHg; intolerable symptoms such as nausea, vomiting or abdominal pain. ASNC 2026 pp 31-32 still reverses for serious or intolerable side effects. Most effects are self-limiting and need no reversal (Abidov 2018). After regadenoson or dipyridamole, other rescue drugs go after aminophylline, not instead of it (ASNC 2026 pp 22, 25); Wilkinson 2019 treated hypotension with phenylephrine. No document read tests these in children. Our note: mean resting systolic BP in Wilkinson 2019’s children was 90.4 mmHg, so <80 and <90 mmHg do not read across, and ST segments cannot be read in the magnet (Strigl 2009).

Hold before the scan

Caffeine: the day of the examination (SCMR CHD 2013, adenosine); 24 h (Patel 2022); Adult at least 12 h, preferably 24 h, decaffeinated drinks too (ASNC 2026). No guideline read gives a pediatric interval in hours. Fares 2019 says it does not affect regadenoson (9 adults) or dobutamine (no citation); the sources above still hold it.

All sources; beta-blockers before dobutamine
Caffeine, before a vasodilator
PediatricThe day of the examination, for adenosine (also aminophylline and nitrates)SCMR CHD 2013
Pediatric24 h, single-center study protocol, regadenosonPatel 2022
Adult12 h: testing contraindicated if used within itAUC 2023
Adult12–24 h (also theophylline and dipyridamole)SCMR 2020
AdultAt least 12 h, preferably 24 h, decaffeinated coffee, tea and soda too (also theophylline and caffeine-containing drugs, p20). Within 12 h a contraindication, within 24 h a caution. Advanced liver disease: ideally 1 week, or dobutamineASNC 2026 Tables 3, 4, p43
AdultA randomized trial found caffeine reduced regadenoson defects on nuclear imaging, as ASNC 2026 reports it; the trial itself was not read. Current methylxanthine medication: dobutamine instead. No document read addresses an infant on caffeine citrateASNC 2026 pp 28, 43
AdultDipyridamole, at least 48 h, before regadenoson or adenosineASNC 2026 Table 3
AdultAt least 12 h, regadenoson label, before imagingFDA label
AdultAt least 12 h, study protocolKaramitsos 2010
AdultAt least 24 h, study protocolVasu 2013
Review1 to 2 days (also theophylline)Robbers-Visser 2009
ReviewReduces sensitivity to adenosine and dipyridamole; no effect on regadenoson or dobutamineFares 2019 Table 2
AdultCoffee under 4 h before regadenoson: no effect on hyperemia by T1 mapping, in 9 adults. The source of the “no effect” entry in Fares 2019.van Dijk 2017
Before dobutamine
PediatricBeta-blockers and caffeine, at least 24 hStrigl 2009
PediatricBeta-blockers, 3 daysStagnaro 2023
PediatricHold beta-blockers, avoid caffeine: no interval givenAHA 2026 Table 2
AdultBeta-blockers and nitrates, 12–24 hSCMR 2020
AdultBeta-blockers, 4–5 half-lives unless unsafe. Caffeine and theophylline at least 12 h, preferably 24 h, and dipyridamole at least 48 h, in case a vasodilator is substitutedASNC 2026 p29
Median 36 yNitrates, beta-blockers, calcium antagonists, other negative inotropes and chronotropes, at least 48 hAttanasio 2025

For stress CMR in children

Key points

Sources and how this page was checked

Main reference

Where the proposed doses trace to

FDA labels, read on DailyMed

Full text read

Review articles, labelled as such where used

Abstract only

As printed in the sources

Not covered, not read

How it was checked